434 related articles for article (PubMed ID: 24373113)
21. Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy.
Haldrup S; Lapolla A; Gundgaard J; Wolden ML
J Med Econ; 2020 Mar; 23(3):271-279. PubMed ID: 31526202
[No Abstract] [Full Text] [Related]
22. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation.
Evans M; McEwan P; Foos V
J Med Econ; 2015 Feb; 18(2):96-105. PubMed ID: 25325179
[TBL] [Abstract][Full Text] [Related]
23. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
25. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
Ericsson Å; Lundqvist A
Appl Health Econ Health Policy; 2017 Apr; 15(2):237-248. PubMed ID: 28063135
[TBL] [Abstract][Full Text] [Related]
26. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
[TBL] [Abstract][Full Text] [Related]
27. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.
Einhorn D; Handelsman Y; Bode BW; Endahl LA; Mersebach H; King AB
Endocr Pract; 2015 Aug; 21(8):917-26. PubMed ID: 26121451
[TBL] [Abstract][Full Text] [Related]
28. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034
[No Abstract] [Full Text] [Related]
29. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.
Landstedt-Hallin L; Gundgaard J; Ericsson Å; Ellfors-Zetterlund S
Curr Med Res Opin; 2017 Apr; 33(4):647-655. PubMed ID: 28035840
[TBL] [Abstract][Full Text] [Related]
30. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
32. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
[TBL] [Abstract][Full Text] [Related]
33. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources.
Heller SR; Frier BM; Hersløv ML; Gundgaard J; Gough SC
Diabet Med; 2016 Apr; 33(4):471-7. PubMed ID: 26179360
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes.
Cheng H; Wan X; Ma J; Wu B
Clin Ther; 2019 Mar; 41(3):445-455.e4. PubMed ID: 30713016
[TBL] [Abstract][Full Text] [Related]
35. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
[TBL] [Abstract][Full Text] [Related]
36. Using 2nd generation basal insulins in type 2 diabetes: Costs and savings in a comparative economic analysis in Italy, based on the BRIGHT study.
Napoli R; Fanelli F; Gazzi L; Larosa M; Bitonti R; Furneri G
Nutr Metab Cardiovasc Dis; 2020 Oct; 30(11):1937-1944. PubMed ID: 32912786
[TBL] [Abstract][Full Text] [Related]
37. [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
Lüdemann J; Milek K; Wilhelm B; Segner A; Jaeckel E
MMW Fortschr Med; 2014 Oct; 156 Suppl 3():89-97. PubMed ID: 25417447
[TBL] [Abstract][Full Text] [Related]
38. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
Jendle J; Ericsson Å; Ekman B; Sjöberg S; Gundgaard J; da Rocha Fernandes J; Mårdby AC; Hunt B; Malkin SJP; Thunander M
J Med Econ; 2020 Nov; 23(11):1311-1320. PubMed ID: 32746676
[TBL] [Abstract][Full Text] [Related]
39. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Mathieu C; Hollander P; Miranda-Palma B; Cooper J; Franek E; Russell-Jones D; Larsen J; Tamer SC; Bain SC;
J Clin Endocrinol Metab; 2013 Mar; 98(3):1154-62. PubMed ID: 23393185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
